SCHEMBL5365092

SCHEMBL5365092

Cc1ccc(C2(C(=O)NCCc3ccc(C)c(C)c3)CCCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
CNR1 P21554 1/20 0.44
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
IDO1 P14902 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 1/20 0.43
HTR1E P28566 1/20 0.43
S1PR3 Q99500 1/20 0.43
CHRM5 P08912 1/20 0.42
CHRM3 P20309 1/20 0.42
HDAC4 P56524 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FPR3 P25089 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
CHRM2 P08172 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14491560 0.90 SMN1; SMN2 (0.54) SMN1; SMN2HTTCNR1ERCC1ERCC4
SCHEMBL14491558 0.87 HDAC4 (0.51) SMN1; SMN2HTTCNR1ERCC1ERCC4
SCHEMBL5351946 0.86 CHRM2 (0.50) SMN1; SMN2HTTERCC1ERCC4IDO1
SCHEMBL5357137 0.85 SMN1; SMN2 (0.49) SMN1; SMN2HTTERCC1ERCC4IDO1
SCHEMBL5363274 0.84 HDAC4 (0.55) SMN1; SMN2HTTCNR1NPSR1MAPT
SCHEMBL5358045 0.84 ALDH1A1 (0.52) SMN1; SMN2HTTERCC1ERCC4IDO1
SCHEMBL5352502 0.84 IDO1 (0.53) SMN1; SMN2HTTCNR1IDO1MAPT
SCHEMBL14516609 0.84 OPRM1 (0.49) SMN1; SMN2HTTCNR1ERCC1ERCC4
SCHEMBL2863161 0.79 ERCC1 (0.58) SMN1; SMN2HTTERCC1ERCC4NPSR1
SCHEMBL14491561 0.78 SMN1; SMN2 (0.56) SMN1; SMN2HTTERCC1ERCC4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 SMN1; SMN2 4281/4885HTT 1708/4885CNR1 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.